RareStone is a therapeutic platform company focused on developing innovative therapies for rare disease patients with unmet medical needs in China. We were founded in 2019, by two Fidelity VCs, Eight Roads, F-Prime, and Vivo Capital due to the favorable changing regulatory, legal, and financial environment reforms to form RareStone. We completed an $80 million, Series A funding helps to advance the vision of creating the very first rare disease platform company in China.
Our mission is to build the first rare disease ecosystem in China and in doing so, enable extraordinary people to live more ordinary lives. In addition to developing and marketing rare disease drugs, RareStone aims to establish a patient-centric platform which educates people on rare, pediatric, and orphan diseases, trains doctors on diagnosis and treatment, and helps doctors develop a full disease management protocol. RareStone is headquartered in Shanghai and has offices in Beijing, China and Cambridge, Mass.